HM Revenue and Customs has halted plans to impose VAT on medicines provided free of charge to patients following clinical trials, after a direct confrontation with the pharmaceutical industry. The pause follows warnings from manufacturers, led by Bayer, that the proposed tax interpretation would render early-access schemes for critically ill patients financially unworkable in the UK.
The dispute centres on HMRC's classification of medicines supplied under compassionate use and early-access schemes as taxable transactions. These schemes allow patients with life-threatening conditions to continue receiving an experimental drug after a clinical trial ends, while formal NHS approval and commissioning remains pending. Under the previous understanding, such supplies were not subject to VAT. HMRC's revised position generated unexpected tax liabilities running into the tens of millions of pounds for individual manufacturers.
Bayer responded by suspending new patient enrolments across its compassionate use programmes, citing tax liabilities it described as insurmountable under the new interpretation. The decision brought the human consequences of the dispute into immediate focus. Patients at the end of trial periods who would ordinarily transition into a compassionate use scheme faced an interruption in treatment for which neither the manufacturer nor the NHS had anticipated or budgeted.
The Association of the British Pharmaceutical Industry framed the levy as a direct threat to the UK's stated ambition to be a leading destination for life sciences investment. The ABPI argued that taxing medicines donated to critically ill patients undermined the commercial logic of running compassionate use schemes in Britain and would reduce the attractiveness of the UK as a location for global clinical trials. That argument carried weight given the government's own commitments, set out in its 10-year health plan, to accelerate clinical trial setup times and expand patient access to innovative therapies.
The NHS impact extends beyond individual patients. For those with conditions where treatment interruption carries serious clinical risk, the withdrawal of compassionate use supply creates what health officials have described as an unfunded mandate. Integrated Care Boards, already under financial pressure, would face a choice between sourcing drugs at full commercial cost to maintain continuity of care, or managing the clinical consequences of abrupt treatment cessation. Neither option is straightforward, and neither was anticipated in local commissioning budgets.
Beyond the immediate patient population, clinicians and researchers have raised concerns about the effect on clinical trial recruitment. If manufacturers cannot guarantee post-trial access without incurring punitive tax costs, the UK becomes a less predictable environment for trial sponsors. That uncertainty reduces the research activity that currently brings both clinical benefit and financial subsidy to NHS institutions hosting trials.
HMRC's position was partly informed by recent Upper Tribunal rulings on VAT rebates in the pharmaceutical sector, which had encouraged a more assertive approach to tax recovery from drug manufacturers. The Treasury's argument rests on the principle of fiscal neutrality, the position that commercial actors should not gain tax advantage through the mechanism by which they distribute products. The pharmaceutical industry contends that applying that principle to medicines supplied without charge to dying patients conflates commercial transactions with clinically motivated donations.
Enforcement action has now been paused while the Department of Health and Social Care and the Treasury negotiate a longer-term resolution. The nature of that settlement, and whether it will result in a formal VAT exemption for medicines supplied under clinically justified free-of-charge schemes, has not been confirmed. Both departments have declined to set a timetable for the outcome of those discussions.
The pause provides short-term relief for manufacturers and for patients currently dependent on compassionate use access. It does not resolve the underlying question of how HMRC classifies such supplies, nor does it provide the legal certainty that pharmaceutical companies say is necessary before they will recommit to new patient enrolments. Until a permanent arrangement is codified, the viability of early-access schemes in the UK remains contingent on the outcome of negotiations that are, at present, ongoing.
